Navigation Links
3SBio Inc. Schedules Unaudited First Quarter 2011 Results
Date:5/3/2011

SHENYANG, China, May 3, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its first quarter 2011 unaudited financial results after the NASDAQ stock market  closes on Wednesday, May 11, 2011 at 8:00pm (US Eastern ).

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00am (US Pacific) / 8:00am (US Eastern) / 8:00pm (Beijing) on Thursday, May 12, 2011 to discuss its first quarter 2011  unaudited financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 64963899

Local dial-in:China landline  

800-819-0121China mobile

400-620-8038Hong Kong  

852-2475-0994International toll-free dial-in:Hong Kong

800930346United Kingdom  

080-8234-6646United States  

1-866-519-4004International toll dial-in: 65 6723 9381

Replay- Conference ID: 64963899

A telephone replay will be available two hours after the call until May 19, 2011 at:

International dial-in:

61-2-8235-5000United States dial-in:

1-866-214-5335WebcastA live webcast of the conference will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/3SBio2011Q1

A replay of the webcast will be available within one hour after the conclusion of the call.

About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 700 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Investor ContactsBo Tan

Chief Financial Officer

3SBio Inc.

Tel: +86-24-2581-1820

Email: ir@3SBio.comTom Folinsbee

Director of Investor Relations

3SBio Inc.

Tel: +852-8191-6991

Email: ir@3SBio.com
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... (PRWEB) , ... January 20, 2017 , ... ... consulting and resource to the healthcare industry ( http://www.gandlscientific.com ), has announced the ... expanding team of clinical and scientific consultants and contractors. This is the latest ...
(Date:1/21/2017)... PARSIPPANY, N.J. , Jan. 20, 2017 /PRNewswire/ ... the "Company"), a company that provides clinically useful ... that it has entered into a securities purchase ... aggregate of 855,000 shares of common stock in ... placement, the Company has agreed to sell to ...
(Date:1/21/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, today presented data from two clinical studies ... American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium ... In a Phase Ib/II study of napabucasin – ... stemness pathways by targeting STAT3 – colorectal cancer (CRC) ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:1/19/2017)... PUNE, India , January 19, 2017 According ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market ... 9.6% from 2016 to 2022. In 2015, Asia-Pacific dominated ... both public and private sectors. Continue Reading ... ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata Technologies, ... for the homecare industry, including Electronic Visit Verification™ ... expert, Justin Jugs, as Senior Vice President of ... 15 years of homecare experience to Sandata, where ... strategic plans to align Sandata,s suite of solutions ...
(Date:1/11/2017)... DES MOINES, Iowa , Jan. 11, 2017 /PRNewswire/ ... another industry first with the release of its patent-pending ... to quickly and reliably perform calibrations, securely upload data ... more flexibility for the customer. "Fighting drunk ... not only for the public at large, but also ...
Breaking Biology News(10 mins):